Aquapheresis Efficacy in Outpatients With Decompensated Heart Failure
Status:
Withdrawn
Trial end date:
2021-07-27
Target enrollment:
Participant gender:
Summary
With this research the Investigators hope to learn if early aquapheresis in an outpatient
setting will improve congestive heart failure symptoms in outpatients with decompensated
heart failure who have been refractory to high dose diuretics. In previous trials in
inpatient settings, aquapheresis has been demonstrated to improve quality of life and reduce
hospital visits for those who have undergone the treatment. This study is one of the first to
evaluate the effectiveness of aquapheresis in veterans with congestive heart failure in an
outpatient setting.
The aquapheresis device, Aquadex FlexFlow® System, manufactured by CHF Solutions™,
Minneapolis, MN, has been approved by the Food and Drug Administration (FDA) for removing
excess sodium and fluid from patients suffering from volume overload, like in congestive
heart failure.